MDedge Cardiocast-logo

MDedge Cardiocast

Health & Wellness Podcasts

MDedge Cardiocast is the weekly podcast from Cardiology News.

MDedge Cardiocast is the weekly podcast from Cardiology News.

Location:

United States

Description:

MDedge Cardiocast is the weekly podcast from Cardiology News.

Language:

English

Contact:

240-221-2400


Episodes

Top stories from the American Heart Association scientific sessions

12/27/2019
ISCHEMIA trial hailed as practice changing The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves. DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events in HFrEF patients with no diabetes. Colchicine cut post-MI CVD events Colchicine fulfilled the promise first seem in CANTOS that anti-inflammatory treatment can reduce...

Duration:00:08:25

Vascepa gains event-reduction nod; diabetes ups ischemic risks

12/20/2019
Vascepa approved for cardiovascular risk reduction The FDA’s decision on cutting events in high-risk patients was based primarily on the REDUCE-IT trial. ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding Novel oral anticoagulants may be preferred over warfarin in patients with diabetes and AFib. HHS drug importation proposals aim to address high costs Trump administration drops key health care proposal on day of impeachment vote. End ‘therapeutic nihilism’...

Duration:00:08:59

Post-STEMI events less likely in women; bariatric surgery may lower stroke risk

12/13/2019
Women have fewer cardiovascular events after non–ST-segment elevation ACS But they also remain undertreated with guideline-directed therapies. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * FDA panel rejects vernakalant bid for AFib cardioversion indication Eleven years after the first attempt of the antiarrhythmic agent, the FDA panel voted resoundingly against approval. Bariatric surgery tied...

Duration:00:08:10

New trick for old drug; Vascepa cost effective for CV reduction

12/6/2019
Icosapent ethyl cost effective in REDUCE-IT analysis Treatment with the fish-derived drug Vascepa for CV event reduction is more effective and less costly than placebo. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * DAPA-HF: Dapagliflozin benefits regardless of age, HF severity The SGLT2 inhibitor had similar efficacy in the elderly and across the spectrum of baseline symptom status. Colchicine...

Duration:00:07:55

Card Talk: TAVR and glass ceilings

11/29/2019
This week’s Cardiocast is devoted entirely to Card Talk with cardiologist brothers Jim and Jerry Dwyer. They welcome two structural interventionalists at the Structural Heart and Valve Center at Emory Healthcare, Kendra J. Grubb, MD, and Isida Byku, MD. Both followed a unique track, training in both cardiac surgery and interventional cardiology and practicing in the fast-moving field of structural heart disease. * * * Help us make this podcast better! Please take our short listener...

Duration:00:43:52

ISCHEMIA trial, DAPA-HF, and valsartan recall: AHA Special

11/26/2019
In this special meeting edition of the Cardiocast, MDedge Cardiology editor Catherine Hackett is joined by MDedge reporters Mitchel L. Zoler, Bruce Jancin, and Richard Mark Kirkner. The MDedge cardiology team reviews three big stories from the 2019 annual scientific sessions of the American Heart Association in Philadelphia. * * * Help us make this podcast better! Please take this short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * ISCHEMIA trial hailed as...

Duration:00:32:05

Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF

11/22/2019
ISCHEMIA trial hailed as practice changing The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events in HFrEF patients with no...

Duration:00:09:26

Pot heightens stroke, arrhythmia risks; keeping low LDL and BP slashes lifetime heart risk

11/15/2019
Getting high heightens stroke, arrhythmia risks Cannabis use or abuse among the young was associated with adverse cardiovascular consequences in two studies. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * Bempedoic acid cuts LDL by 15% in patients with high levels despite maximal treatment CLEAR Wisdom may fill a niche for patients who can't get levels down. Low LDL-C and blood pressure can...

Duration:00:08:44

How risk factors in childhood translate to CV outcomes in adulthood

11/8/2019
Closing the missing link between childhood risk factors and adult cardiovascular outcomes Prescient childhood cohort studies launched in the 1970s are paying off. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * Metabolic signs of adult diabetes apparent in very young children Disturbed HDL cholesterol metabolism may be one of the earliest features of type 2 diabetes. Sacubitril/valsartan...

Duration:00:09:16

Driving while defibrillating; hypertension holds greater risk in black patients

11/1/2019
Patients frequently drive too soon after ICD implantation Many patients didn’t recall ever receiving instruction about when to drive again. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * One-third of CVD disease in blacks linked to hypertension A large analysis suggests intervention throughout all ages could have substantial impact. Cancer overtakes CVD as cause of death in high-income...

Duration:00:08:34

AFib hits Native Americans hard; TAVR shown durable, safe after 5 years

10/25/2019
Strong showing for TAVR after 5 years in PARTNER 2A Transcatheter and surgical aortic valve replacement had similar rates of death or disabling stroke. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * Patiromer allows more CKD patients to continue on spironolactone After 12 weeks, 86% of the patiromer patients remained on spironolactone, vs. 66% of the placebo patients. Native Americans appear to...

Duration:00:08:20

Practice changing prevention data from ESC 2019 Part II

10/22/2019
MDedge reporters discuss the latest in practice-changing data from the 2019 annual congress of the European Society of Cardiology in Paris. Join Mitchel L. Zoler, Bruce Jancin, Kari Oakes, and MDedge Cardiology editor Catherine Hackett as they discuss what they reported from the annual meeting.

Duration:00:42:58

Statins tied to skin, soft tissue infections; new Card Talk episode

10/18/2019
Statin use linked to risk of skin and soft tissue infections Use of statins was associated with increased risk of SSTIs at an average of 91, 182, and 365 days. Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APS Patients who took rivaroxaban experienced almost two times as many thrombotic events as patients who took dose-adjusted vitamin K antagonists. HHS floats Stark/anti-kickback revisions to support value-based care Health law attorneys say reforms...

Duration:00:42:20

Troponin protocol rapidly rules out MI; hidden risk of moderate aortic stenosis

10/11/2019
Novel cardiac troponin protocol rapidly rules out MI Three-quarters of patients who presented with suspected acute coronary syndrome were safely discharged from ED without hospital admission. Study questions preemptive TEVAR for extended type A dissections Interim results from a single-center study show that preemptive TEVAR may not be necessary for type A aortic dissections. TAVR, SAVR share same infective endocarditis risk Be aware, be careful, and provide appropriate antibiotic...

Duration:00:09:33

Sun sets on longer DAPT after PCI; inactivity boosts post-MI risk

10/4/2019
Smoking and inactivity are the most powerful lifestyle risk factors after an MI Insufficient activity beats out obesity or above-target LDL cholesterol. Ticagrelor monotherapy tops DAPT for high-risk PCI patients TWILIGHT findings support move to shorter dual-antiplatelet therapy. Panel releases guidelines for red meat, processed meat consumption "This assessment may be excessively pessimistic; indeed, we hope that is the case." Remember that preeclampsia has a ‘fourth...

Duration:00:09:34

Cardiology dead last as women’s IM subspecialty choice

9/27/2019
Cardiology dead last as women’s IM subspecialty choice Women in internal medicine residencies were more likely than men to report that they had never considered cardiology as a career choice. Beta-blockers effective, safe for HFrEF with renal dysfunction Their role is solidified for essentially all such heart failure patients, regardless of their renal function. Heart failure score derived from machine learning predicts risk in diabetes patients Highest WATCH-DM scores linked to 5-year...

Duration:00:08:36

An antiplatelet surprise; Europeans go low in cholesterol guidelines

9/20/2019
Prasugrel bests ticagrelor in ACS in surprise findings ISAR-REACT 5 was the first-ever direct head-to-head look at two potent P2Y12 inhibitors in this setting. European cholesterol guidelines push LDL targets below 55 mg/dL PCSK-9 inhibitors are elevated to a top-tier recommendation in very-high-risk patients. Drug doses for heart failure could possibly be halved for women Women reached the highest level of drug efficacy at half the doses of ACE inhibitors or ARBs and...

Duration:00:09:57

SGLT-2 inhibitors and more practice changing data from ESC 2019

9/16/2019
MDedge reporters discuss the latest in practice-changing data from the 2019 annual congress of the European Society of Cardiology in Paris. Join Mitchel L. Zoler, Bruce Jancin, Kari Oakes, and MDedge Cardiology editor Catherine Hackett as they discuss what they reported from the annual meeting.

Duration:00:22:04

Overweight BMI surpasses 'normal' and introducing the 'Card Talk' segment

9/13/2019
We introduce a brand new format with Jerome Dwyer, MD, brother of our host, Jim Dwyer, MD, for a new segment that we're calling 'Card Talk' where Dr. Jim and Dr. Jerry talk about the current clinical state of cardiology and take a peek into the future. This week in cardiology news: Survival at ‘overweight’ BMI surpasses ‘normal’ Visceral fat linked to sixfold increase in masked hypertension New class of drug safely halved LDL cholesterol in ORION-11

Duration:00:41:18

Dapagliflozin transforms into heart failure drug

9/6/2019
DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug Proof that dapagliflozin significantly helped heart failure patients without diabetes recategorizes the drug as a major agent for treating heart failure. New hypertension cases halved with community-wide salt substitution Social marketing principles achieved near-universal salt replacement, village by village, in rural Peru. Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable...

Duration:00:10:22